• Biogen Q2 2026 revenue rose 3% to $2.74 billion, while GAAP net income attributable to shareholders fell 85% to $97 million.
• GAAP diluted EPS dropped 85% to $0.66; non-GAAP diluted EPS slid 34% to $3.60.
• Growth Portfolio revenue climbed 24% to $1.06 billion, topping the Legacy MS Portfolio, which fell 14% to $767 million.
• GAAP cost of sales increased 28% to $777 million; GAAP core OpEx rose 26% to $1.24 billion.
• Apellis integration remained on track, with the transaction expected to be accretive to non-GAAP diluted EPS in 2027 and at least $250 million run-rate synergies by end-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.